AngioDynamics Short Interest Up 47.5% in April (ANGO)
AngioDynamics (NASDAQ:ANGO) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 752,009 shares, a growth of 47.5% from the April 15th total of 509,873 shares, AnalystRatingsNetwork reports. Based on an average daily volume of 170,985 shares, the days-to-cover ratio is currently 4.4 days. Approximately 3.0% of the company’s shares are short sold.
A number of analysts have recently weighed in on ANGO shares. Analysts at Raymond James cut their price target on shares of AngioDynamics from $19.00 to $18.00 in a research note on Friday. Separately, analysts at TheStreet downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Thursday, April 17th. Finally, analysts at Canaccord Genuity raised their price target on shares of AngioDynamics from $15.50 to $16.25 in a research note on Thursday, April 10th.
AngioDynamics (NASDAQ:ANGO) opened at 14.02 on Monday. AngioDynamics has a 1-year low of $10.53 and a 1-year high of $19.00. The stock has a 50-day moving average of $14.3 and a 200-day moving average of $15.61. The company has a market cap of $494.5 million and a P/E ratio of 137.62.
AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Wednesday, April 9th. The company reported $0.16 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.09 by $0.07. The company had revenue of $88.20 million for the quarter, compared to the consensus estimate of $86.85 million. During the same quarter last year, the company posted $0.08 earnings per share. AngioDynamics’s revenue was up 8.1% compared to the same quarter last year. On average, analysts predict that AngioDynamics will post $0.30 earnings per share for the current fiscal year.
AngioDynamics, Inc designs manufacture and sell a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.